Streetbeat News

Analyst Ratings

VBTX

Raymond James analyst Daniel Tamayo has upgraded Veritex Holdings (NASDAQ:VBTX) from Market Perform to Strong Buy, setting a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:56 pm

DADA

Dada Nexus shares rose following the company's Q2 earnings report and an upgrade from Citigroup, which changed its rating from Sell to Neutral.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:55 pm

TCBI

Raymond James analyst Michael Rose has upgraded Texas Capital Bancshares (NASDAQ:TCBI) from Market Perform to Outperform, setting a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:55 pm

NYCB

New York shares are experiencing an uptick following an upgrade by Raymond James from Underperform to Market Perform.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:52 pm

SNV

Raymond James analyst Michael Rose has upgraded Synovus Financial (NYSE:SNV) from Market Perform to Outperform, setting a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:50 pm

MMSI

Needham analyst Mike Matson has maintained a Buy rating on Merit Medical Systems (NASDAQ:MMSI) and raised the price target from $105 to $109.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:44 pm

ASND

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and raised the price target from $264 to $289.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:42 pm

MU

UBS analyst Timothy Arcuri maintains a Buy rating on Micron Technology but lowers the price target from $153 to $135.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:40 pm

VRNA

HC Wainwright & Co. has reiterated its Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a price target of $36, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:38 pm

NEM

UBS analyst Daniel Major has maintained a Buy rating on Newmont (NYSE:NEM) and increased the price target from $50 to $65.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 3:37 pm